EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.
See also List of investigational hallucinogens and entactogens List of investigational antidepressants
References
External links Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin - atai Life Sciences (November 21, 2023) - LinkedIn